
Vofatamab
CAS No. 1312305-12-6
Vofatamab( —— )
Catalog No. M36756 CAS No. 1312305-12-6
Vofatamab (B-701) is a fully human monoclonal antibody targeting FGFR3. Vofatamab has potential anticancer and antitumor activity and is often used in combination with other compounds to treat cancer.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 515 | Get Quote |
![]() ![]() |
5MG | 812 | Get Quote |
![]() ![]() |
10MG | 1302 | Get Quote |
![]() ![]() |
25MG | 1822 | Get Quote |
![]() ![]() |
50MG | 2512 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameVofatamab
-
NoteResearch use only, not for human use.
-
Brief DescriptionVofatamab (B-701) is a fully human monoclonal antibody targeting FGFR3. Vofatamab has potential anticancer and antitumor activity and is often used in combination with other compounds to treat cancer.
-
DescriptionVofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetFGFR
-
RecptorFGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1312305-12-6
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Andrea Necchi, et al. Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC). Journal of Clinical Oncology 2019 37:7_suppl, 409-409.
molnova catalog



related products
-
FGFR4-IN-1
FGFR4-IN-1 is a potent FGFR4 inhibitor (IC50: 0.7 nM).
-
TAS120
TAS-120 is a novel potent and highly selective FGFR inhibitor used for antitumor treatment.
-
Pemigatinib (INCB054...
Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor.